Related Experiment Video
Updated: Jun 1, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Metastatic lung disease treated with pemetrexed-docetaxel combination chemotherapy
G P Stathopoulos1, Ch Zoublios, J Stathopoulos
1First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece. dr.gps@ath.forthnet.gr
Purpose:
According to the ASCO guidelines 4 cytotoxic agents are used in colorectal cancer. Numerous agents have not been used or tested and thus their effectiveness is not known. Herein we present the preliminary data of a trial whose objective was to investigate the effectiveness to 2 combined agents in patients with heavily pretreated adenocarcinomas.
Methods:
Ten patients have been recruited up until now. Colorectal adenocarcinoma was the primary disease in 7 patients, gastric cancer in 2, and endometrial adenocarcinoma in one. All patients had undergone at least 2 lines of previous chemotherapy during 2-3 years before the trial. The lungs were the only or main site of metastases in all patients. Chemotherapy agents used were pemetrexed 500 mg/m(2) and docetaxel 75 mg/m(2), repeated every 3 weeks, with a plan to administer 6 cycles.
Results:
The mean number of cycles were 3 (range 1-6). Total number of cycles 33. No serious toxicity was detected. One patient had complete response, 3 partial response, 5 stable disease, 1 disease progression. Median survival was 6 months (range 2-12+ months).
Conclusion:
The effectiveness of the pemetrexed-docetaxel combination in heavily pretreated adenocarcinoma patients justifies their use when no other alternative exists.
